IONS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ionis Pharmaceuticals Inc (IONS) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock has strong analyst support with upward price target revisions, a positive technical setup, and hedge fund buying activity. While financials show some mixed results, the company's growth potential in the biotech space and its upcoming product catalysts make it a solid long-term investment.
The technical indicators for IONS are positive. The MACD histogram is above 0 and positively contracting, indicating bullish momentum. The RSI is neutral at 50.054, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above its pivot level of 75.044, with key resistance at 76.937 and support at 73.152.
Analysts have consistently raised price targets, with the latest targets ranging from $83 to $120, and maintain Buy or Overweight ratings.
Hedge funds have increased their buying activity by 242.57% in the last quarter.
The company's Tryngolza product has strong growth potential, with peak sales estimates revised upward.
SwingMax issued a buy signal on 2026-03-26, and the stock has shown a 0.49% price increase since then.
The company's Q4 2025 revenue dropped by -10.26% YoY, and gross margin declined by -2.26% YoY.
No recent news or congress trading data to act as immediate catalysts.
Post-market price change is slightly negative at -0.07%, though not significant.
In Q4 2025, Ionis Pharmaceuticals reported a revenue decline of -10.26% YoY to $203.33M. However, net income improved significantly by 119.83% YoY to -$229.39M, and EPS increased by 113.64% YoY to -1.41. Gross margin slightly declined to 96.09%, down -2.26% YoY. Overall, the financials show mixed results but indicate improvement in profitability metrics.
Analysts are highly positive on IONS, with multiple firms raising price targets and maintaining Buy or Overweight ratings. The average price target is above the current price, with the highest target at $120. Analysts highlight the company's growth potential in severe hypertriglyceridemia and other key areas, positioning it as a strong long-term investment.
